ROCK2 and chronic graft versus host disease: Belumosudil (trade name REZUROCK) is a preferential ROCK2 inhibitor, developed as an investigational drug and used in the ROCKstar Study78, and is currently FDA-approved for treatment of chronic graft-versus-host disease.